Adlai Nortye ANL
NASDAQ ANL
$16.04 +0.04 (+0.25%)
As of: Oct 1, 2026 · 10:12 AM EDT

Adlai Nortye (ANL) Current Deferred Revenue (2023 - 2025)

Updated

Adlai Nortye (ANL) recorded Current Deferred Revenue of $5 million in Q2 2025.

Analysis

Adlai Nortye (ANL) Current Deferred Revenue (2023 - 2025) Analysis & Trends

  • Across earlier years, Current Deferred Revenue came in at $5 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Adlai Nortye 549.39 Mn 450.09 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 5.00 Mn
Dec 31, 2024 5.00 Mn
Dec 31, 2023 5.00 Mn
API Access

Adlai Nortye Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ANL&period=max&api_key=YOUR_API_KEY